The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells (Q38962245)

8 September 2017

The Akt inhibitor MK-2206 enhances the cytotoxicity of paclitaxel (Taxol) and cisplatin in ovarian cancer cells (English)

1 reference

8 September 2017

1 reference

1 reference

1 reference

1 reference

6

1 reference

8 September 2017

Lih-Ching Hsu

7

0 references

Jih-Hwa Guh

object named as

Jih-Hwa Guh

5

0 references

author name string

Ying-Hsi Lin

1

1 reference

8 September 2017

Bert Yu-Hung Chen

2

1 reference

8 September 2017

Wei-Ting Lai

3

1 reference

8 September 2017

Shao-Fu Wu

4

1 reference

8 September 2017

28 August 2014

1 reference

Naunyn-Schmiedeberg's Archives of Pharmacology

8 September 2017

1 reference

8 September 2017

388

1 reference

8 September 2017

19-31

1 reference

8 September 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s00210-014-1032-y

8 September 2017

0 references

cites work

Ovarian cancer: strategies for overcoming resistance to chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Role of phosphatidylinositol 3-kinase/AKT as a survival pathway against CYP2E1-dependent toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

The mTOR inhibitor rapamycin suppresses DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

The PI3K pathway as drug target in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Treatment of ovarian cancer: new strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Genomic complexity and AKT dependence in serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Centrosome abnormalities in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Combination of an allosteric Akt Inhibitor MK-2206 with etoposide or rapamycin enhances the antitumor growth effect in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Targeting the phosphoinositide 3-kinase pathway in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Activation of the PI3K/Akt pathway and chemotherapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

A PP1-binding motif present in BRCA1 plays a role in its DNA repair function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00210-014-1032-Y

Mechanism of activation of protein kinase B by insulin and IGF-1

21 January 2018

1 reference

12 December 2020

Advances in the management of epithelial ovarian cancer

1 reference

12 December 2020

Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines

1 reference

12 December 2020

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer

1 reference

12 December 2020

10.1007/S00210-014-1032-Y

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

0 references

1 reference